Ireland - English - HPRA (Health Products Regulatory Authority)

janssen biologics b.v. - abciximab - solution for inj/inf - 2 mg/ml - platelet aggregation inhibitors excl. heparin

Singapore - English - HSA (Health Sciences Authority)

eli lilly (singapore) pte ltd - abciximab - injection - 2 mg/ml

Canada - English - Health Canada

janssen inc - abciximab - solution - 2mg - abciximab 2mg - miscellaneous therapeutic agents

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

janssen-cilag ltd - abciximab - solution for injection - 2mg/1ml

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

شركة الشرق الاوسط للصناعات الدوائية - middle east pharmaceutical and chemical industries - abciximab 10 mg/5ml - 10 mg/5ml

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

janssen biologics b.v. - abciximab 2 mg/ml - solution for injection/infusion - abciximab

New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - abciximab 2 mg/ml - solution for injection - 2 mg/ml - active: abciximab 2 mg/ml excipient: dibasic sodium phosphate dihydrate monobasic sodium phosphate monohydrate polysorbate 80 sodium chloride water for injection - reopro is indicated as an adjunct to heparin and aspirin for: percutaneous coronary intervention: the prevention of ischaemic cardiac complications (death, myocardial infarction or need for urgent intervention) in patients during or following percutaneous coronary intervention (balloon angioplasty, atherectomy and stent placement).